As our data indicate that SFRP2 causes a molecular and phenotypical switch of PC3 cancer cells towards more osteoblast-like cells, these novel findings may help to monitor the osteotropic activity of metastatic prostate cancer cells in all phases of bone metastasis. Here, SFRP2 is linked to prostate cancer.